BEO Therapeutics AG develops oral microbiome therapies to counteract diseases caused by metabolic waste products, such as gouty arthritis and (cardio-)metabolic disorders. The company focuses on QPS‑designated bacteria to rebalance the gut microbiome and is evaluating BEO 001 in phase 1/2 clinical trials in patients with hyperuricemia.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Oral microbiome therapies for the treatment of diseases through metabolic waste products, including gouty arthritis and cardiometabolic conditions; chronic use, rebalancing the gut microbiome and urate metabolism.
Clinical development of BEO 001
Clinical development of BEO 001 with two Phase 1/2 studies in more than 100 patients with hyperuricemia to evaluate safety, mechanism of action and efficacy.
Knowledge
No knowledge articles yet
Once BEO Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.